Polycythemia Vera is an active area of clinical research and therapeutic development covered by The Life Science Feed. Our editorial team tracks the latest clinical trials, treatment guidelines, regulatory updates, and scientific advances relevant to Polycythemia Vera. Browse the latest articles below for in-depth analysis and evidence-based clinical insights.
Haematocrit targets: Is 45% still the right threshold for phlebotomy?
The 45% haematocrit threshold for phlebotomy in polycythaemia vera is a long-standing guideline, but its evidence base warrants re-examination for optimal patient outcomes.
Why molecular response in polycythemia vera remains an elusive endpoint
A network meta-analysis of polycythemia vera treatments was not feasible due to substantial heterogeneity in study designs and outcome definitions.
• Aug 28 – 31ERS 2026 • Barcelona, ES 
• Sep 5 – 9EASD 2026 • Milan, IT 
• Sep 28 – Oct 2UEG Week 2026 • Vienna, AT 
• Oct 3 – 7Joint ACTRIMS-ECTRIMS 2026 • Toronto, CA 
• Oct 21 – 23ESMO 2026 • Madrid, ES • Oct 23 – 27AHA 2026 • Chicago, US 
• Nov 7 – 9ACR 2026 • Washington DC, US • Nov 14 – 19ASH 2026 • New Orleans, US • Dec 12 – 15ACC.27 Together With WCC • Houston, US • Apr 10 – 12ESC 2026 • Munich, DE • Aug 28 – 31ERS 2026 • Barcelona, ES • Sep 5 – 9EASD 2026 • Milan, IT • Sep 28 – Oct 2UEG Week 2026 • Vienna, AT • Oct 3 – 7Joint ACTRIMS-ECTRIMS 2026 • Toronto, CA • Oct 21 – 23ESMO 2026 • Madrid, ES • Oct 23 – 27AHA 2026 • Chicago, US • Nov 7 – 9ACR 2026 • Washington DC, US • Nov 14 – 19ASH 2026 • New Orleans, US • Dec 12 – 15ACC.27 Together With WCC • Houston, US • Apr 10 – 12